Horizon Europe is the European Union (EU) funding programme for the period 2021 – 2027, which targets the sectors of research and innovation. The programme’s budget is around € 95.5 billion, of which € 5.4 billion is from NextGenerationEU to stimulate recovery and strengthen the EU’s resilience in the future, and € 4.5 billion is additional aid.
Common challenges in translational cancer research require effective transnational cooperation on prioritised efforts, leveraging national, regional and charity-based resources and appropriate funding schemes. Important achievements of translational cancer research funding by long-term collaboration of national and philanthropy funding organisations have been obtained by the TRANSCAN network under the Seventh Framework Programme for Research and Innovation (2007-2013) and Horizon 2020 (2014-2020).
More efforts are warranted to address the potential for sustainable coordination, the access to and sharing of research data to enhance the understanding of cancer as well as to further the alignment of national, regional and foundation or charity-based cancer research and innovation programmes and activities in Member States and Associated Countries. The EU contribution will not be used to co-fund the grants to third parties described hereunder.
The proposal should address all the following:
100%
Expected EU contribution per project: €5.00 million.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects.
Research and Innovation Foundation
Address: 29a Andrea Michalakopoulou, 1075 Nicosia, P.B. 23422, 1683 Nicosia
Telephone: +357 22205000
Fax: +357 22205001
Email: support@research.org.cy
Website: https://www.research.org.cy/en/
Contact Person:
Mr. George Christou
Scientific Officer
Email: gchristou@research.org.cy